| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT03715153 2017-004420-30 Details | 2023-06-05 Interventional | 3 | 211 | Bumetanide Autism Spectrum… Autistic Disord… Child Developme… Autism Spectrum… | The 6-month efficacy analysis did not show any significant difference between bumetanide versus
placebo in the treatment of ASD in the overall studied population. No unexpected safety
concerns were identified. The sponsor decided to stop the S95008 development and prematurely discontinue the extension period. This decision was not related to unexpected safety concerns. | |||
| NCT03566511 Details | 2023-06-05 Interventional | 2 | 24 | Diazoxide Diabetes Mellit… Diabetes Mellit… Glucose Metabol… Metabolic Disea… Glucose Metabol… Glucose, High B… | Temporarily paused while the MR center develops newer study techniques. We might resume; this
is not a suspension of IRB approval. - | |||
| NCT05886257 Details | 2023-06-02 Interventional | 2 | 0 | Bevacizumab Carcinoma Carcinoma, Hepa… Hepatocellular … | Protocol adjustment - | |||
| NCT02601365 Details | 2023-06-02 Interventional | 1 | 0 | Molgramostim Sargramostim Acute Lung Inju… Pneumonia Respiratory Dis… Respiratory Dis… Acute Respirato… Respiratory Vir… | Clinical Hold FDA - | |||
| NCT00442104 Details | 2023-06-02 Interventional | 2 | 54 | Ganaxolone Spasm Spasms, Infanti… Infantile Spasm… | Sponsor's decision Seizure-free information is not available | |||
| NCT04079088 2019-001847-28 Details | 2023-06-01 Interventional | 2 | 0 | (T,G)-A-L Glatiramer Acet… Interferon beta… Interferon-beta Interferons Multiple Sclero… Sclerosis Relapsing Multi… | Decision to discontinue BIIB061 program was based on lack of stronger preclinical effects of
BIIB061 on remyelination relative to opicinumab, that showed limited clinical efficacy in phase
2 clinical studies. This was not related to safety concerns. - | |||
| NCT03637803 Details | 2023-06-01 Interventional | 1/2 | 63 | Pembrolizumab Carcinoma, Rena… Bladder Cancer Melanoma Non Small Cell … Oncology Renal Cell Carc… Solid Tumor | Sponsor insolvency - | |||
| NCT03145480 Details | 2023-06-01 Interventional | 2 | 3 | Ibrutinib Obinutuzumab Syndrome Richter Syndrom… | Investigator decision to close study - | |||
| NCT04648020 Details | 2023-05-31 Interventional | 2/3 | 190 | Clonidine Mucositis Oropharyngeal N… Stomatitis Chemoradiothera… | Interim Analysis did not meet the pre-defined threshold for efficacy of a 15% absolute
difference in SOM prevention between Validive and placebo. - | |||
| NCT04155190 Details | 2023-05-31 Interventional | 2 | 47 | Veratrum Alkalo… Carcinoma Carcinoma, Basa… Recurrent Basal… | Terminated early due to low blinded event rate - | |||
| NCT02478710 Details | 2023-05-31 Interventional | 4 | 16 | Tobramycin Vancomycin Pneumonia Pneumonia, Vent… | - Data was not collected for the Secondary Outcomes. | |||
| NCT04261036 Details | 2023-05-30 Interventional | 1 | 0 | Ascorbic Acid Infections Urinary Tract I… Catheter-Associ… | Unfortunately, the economic crisis in Lebanon precluded utilization of available funding to
recruit patients at the specified institution. No patients were recruited. - | |||
| NCT05597722 Details | 2023-05-26 Interventional | 4 | 7 | Adderall Amphetamine Dextroamphetami… Post-Acute COVI… Cognitive Impai… Long COVID | Due to the evolving nature of COVID-related cognitive fog, it was determined that the study
would be terminated at this time. The team agreed that it isn't feasible to collect enough data
to evaluate the efficacy of the treatments. - | |||
| NCT05563168 2021-004160-94 Details | 2023-05-26 Interventional | 2 | 0 | Diltiazem COVID-19 Pneumonia | the epidemiological situation has changed considerably. - | |||
| NCT04938388 Details | 2023-05-25 Interventional | 4 | 12 | Semaglutide Diabetes Mellit… Diabetes Mellit… Glucose Metabol… Metabolic Disea… Glucose Metabol… | Principal Investigator no longer at study site. - | |||
| NCT04944654 Details | 2023-05-24 Interventional | 4 | 1 | Emtricitabine Acquired Immuno… HIV Infections Human Immunodef… | Trial set up was delayed, funding support no longer available - | |||
| NCT04933942 Details | 2023-05-24 Interventional | 2 | 0 | Lomustine Disease Progres… Glioblastoma Thrombocytopeni… First Progressi… | Amgen withdrew interest in providing further financial support - | |||
| NCT04876859 Details | 2023-05-24 Interventional | 3 | - | Anesthetics Chronic Pain Osteoarthritis Osteoarthritis,… Hip Osteoarthri… | Main researcher changed institutions, making it unfeasible to be completed by the others
participants. - | |||
| NCT04258423 Details | 2023-05-24 Interventional | 3 | 4 | Everolimus Tacrolimus Renal Insuffici… Kidney Failure | Study was larger than expected and became a burden to faculty and staff resources. - | |||
| NCT04163900 2019-001025-28 Details | 2023-05-24 Interventional | 3 | 773 | Gemcitabine Biliary Tract N… Biliary Tract C… | A pre-planned futility analysis concluded that NUC-1031 plus cisplatin was unlikely to achieve
its primary objective of improving overall survival. Based on the IDMC's recommendation, NuCana
has closed the study. At Interim Analysis 1, the futility boundary for OS was crossed and the study was closed on 02 Mar 2022. Following study closure, data from the 05 April 2022 final data cut-off (30 day follow-up post the last patient last visit) were analysed. In general, the analyses performed on this final database were those that were scheduled to take place at Interim Analysis 2. However, any p-values or CIs obtained are only viewed as descriptive as the study was stopped for futility. |